Yesterday, the Israel Institute for Biological Research (IIBR) announced that it is currently studying the new Omicron variant of the SARS-CoV-2 to assess the extent to which this variant is neutralized by antibodies produced by the BriLifeTM COVID-19 vaccine.
Previously, the IIBR released a scientific report demonstrating effective antibodies against the Delta variant in a sample of patients who were vaccinated with BriLife.
The Omicron variant is, by far, the most complicated of all mutations studied thus far. While the Delta variant has 18 spike protein mutations, experts have identified 43 spike protein mutations for Omicron. It’s important to note that while the number of mutations does not necessarily define the severity of illness for those infected, a larger number of mutations may pose additional challenges to the immunity produced by vaccines targeting the original wild-type virus.
NRx will continue to provide updates as they become available about the BriLife COVID-19 vaccine, its development, and data produced from laboratory experiments and clinical trials. We are fortunate that the IIBR, as a government laboratory, is organized to receive new variants of the virus as they are detected and isolated.
Please check the NRx website often to ensure you receive the most current information about the BriLife COVID-19 vaccine and all of our efforts to advance the NRx pipeline. Click this link to subscribe to our mailing list. https://www.nrxpharma.com
Thank you for following our journey.
-Jonathan
Cautionary Note Regarding Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the company’s strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the company’s management.
The company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.
